LakeShore Biopharma Co EBIT

LakeShore Biopharma Co (LSB) currently reports a EBIT of $-200M as of March 2024. That compares with $-9.4M in the prior-year period — down 2021.5% year over year. That is below the sector sector average of $-63M. Use the charts on this page to explore LakeShore Biopharma Co's EBIT history and peer comparisons.

LakeShore Biopharma Co's EBIT decreased from $-9.4M to $-200M — a 2021.5% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

LakeShore Biopharma Co's EBIT of $-200M is lower than the its sector sector average of $-63M. That is roughly 219.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

LakeShore Biopharma Co reported $-200M in EBIT as of March 2024. That compares with $-9.4M in the prior-year period — down 2021.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-200M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $-63M. From there, open related valuation or income-statement pages for LakeShore Biopharma Co, and consider following LSB for alerts when major investors trade the stock.